Quantum BioPharma Targets Neurological and Wellness Markets with Diversified Pipeline

As neurological disorders become the leading cause of illness and disability worldwide, affecting over one-third of the global population according to the World Health Organization, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is stepping up to address critical unmet needs. The company’s flagship pharmaceutical subsidiary, Lucid Psycheceuticals Inc., is advancing LUCID-MS, a patented new chemical entity designed to target the loss of mobility and function in multiple sclerosis—an area where current drugs fall short. Beyond its neurological pipeline, Quantum BioPharma has also expanded into the wellness market with unbuzzd(TM), a clinically validated alcohol metabolism accelerator that helps sober people up faster, addressing the growing demand for alcohol health and sobriety solutions.

The company’s diversified strategy positions it at the intersection of two high-growth sectors: neurodegenerative disease therapeutics and consumer wellness. With neurological conditions now a top global healthcare challenge, therapies that protect neurons and slow disease progression are more critical than ever. Quantum BioPharma’s approach includes both a novel drug candidate for multiple sclerosis and a consumer-ready product for alcohol metabolism, reflecting a broad commitment to brain health and functional recovery. The news release, disseminated by NetworkNewsWire (NNW), highlights the company’s progress and invites investors to explore further details via the newsroom at https://nnw.fm/QNTM.

NetworkNewsWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, provides comprehensive distribution and syndication services to ensure maximum visibility for companies like Quantum BioPharma. Through its vast network of wire solutions and editorial syndication to 5,000+ outlets, NNW helps clients reach a wide audience of investors and consumers. For Quantum BioPharma, this partnership amplifies the message that innovative approaches to neurological and wellness markets are not just needed but are being actively developed. The full release can be read at Read More>>, where detailed insights into the pipeline and market strategy are available.